Breaking News, Financial News

Financial Report: Roche

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Roche MYTD Revenues: $18.6 billion (+15%) MYTD Earnings: $4.1 billion (+29%) Comments: Pharmaceutical sales increased 18% to $9.3 billion for the half-year. Growth was driven by key oncology drugs (MabThera/Rituxan, Herceptin, Avastin, Xeloda and Tarceva), up 22%, as well as metabolism, (Bonviva/Boniva up 127% to $304 million) transplantation and virology drugs, including increased Tamiflu sales for pandemic stockpiling. Lucentis, Genentech’s recently launched medicine for age-rel...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters